London startup to trial drug preventing cytokine storm in cancer patientsExecutive summary: Poolbeg Pharma is set to trial a drug in six NHS hospitals to prevent cytokine storm, a severe immune reaction, in cancer patients undergoing immunotherapy. If proven effective, the drug could reduce mortality and complications, lower treatment costs, and create a new market niche for adjunctive oncology therapies. Poolbeg Pharma, NHS hospitals, cancer patients, oncology investors. Phase 1 safety data expected within months, followed by Phase 2 trials and regulatory review pending MHRA approval.Poolbeg Pharma will begin a trial of a drug in six NHS hospitals that aims to prevent cytokine release syndrome, a life‑threatening side‑effect of cancer immunotherapy. The trial will assess safety and early efficacy in patients receiving checkpoint inhibitors. Success could introduce a new adjunct therapy and generate a new revenue stream for the startup.Open the full case file on Beyond →
Social Pulse
AI estimate · not scraped